开拓药业(09939.HK)及中国抗体(03681.HK)续挫13%及7.4% 康希诺反覆弹3%
仍未有盈利挂牌第四天的开拓药业-B(09939.HK)继首挂日反覆高见22.95元行人止步,收市仅较上市价20.15元高6.7%後,股价连跌第三天,今天跌破首挂日所造低位20.1元,最低见16.24元,现造17.54元,急挫13%,成交已较昨天全日急增3倍至2,024万股,涉资3.72亿元。
其余未有盈利「B仔股」个别发展。中国抗体制药-B(03681.HK)续跌7.4%报3.9元,远低去年11月上市价7.6元。该公司大股东拟以每股3.5元出售4,133万股予执董兼总裁强静拥有格擎生物。
诺诚健华-B(09969.HK)连跌第二天,今早高开见15.16元受制10天线,掉头失守20天线(14.76元),最低见14.16元,现造14.26元,续跌4.3%;康宁杰瑞制药-B(09966.HK)反覆吐2.6%报18.92元。
不过,华领医药-B(02552.HK)连弹第二天曾重越10天线(4.58元),高见4.61元,现造4.54元,续弹6%。康希诺生物-B(06185.HK)扭两连挫,今天反覆(高低见179元/152元)回升3%报174.9元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.